GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » PB Ratio

Shanghai Henlius Biotech (HKSE:02696) PB Ratio : 6.37 (As of Apr. 23, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-23), Shanghai Henlius Biotech's share price is HK$37.70. Shanghai Henlius Biotech's Book Value per Share for the quarter that ended in Dec. 2024 was HK$5.92. Hence, Shanghai Henlius Biotech's PB Ratio of today is 6.37.

Warning Sign:

Shanghai Henlius Biotech Inc stock PB Ratio (=6.37) is close to 3-year high of 6.4.

The historical rank and industry rank for Shanghai Henlius Biotech's PB Ratio or its related term are showing as below:

HKSE:02696' s PB Ratio Range Over the Past 10 Years
Min: 2.01   Med: 4.37   Max: 12.93
Current: 6.37

During the past 8 years, Shanghai Henlius Biotech's highest PB Ratio was 12.93. The lowest was 2.01. And the median was 4.37.

HKSE:02696's PB Ratio is ranked worse than
82.94% of 1284 companies
in the Biotechnology industry
Industry Median: 2.16 vs HKSE:02696: 6.37

During the past 12 months, Shanghai Henlius Biotech's average Book Value Per Share Growth Rate was 34.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 4.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -9.30% per year.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai Henlius Biotech was 10.90% per year. The lowest was -25.70% per year. And the median was -4.80% per year.

Back to Basics: PB Ratio


Shanghai Henlius Biotech PB Ratio Historical Data

The historical data trend for Shanghai Henlius Biotech's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech PB Ratio Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial 6.69 4.26 3.81 3.15 4.00

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 2.92 3.15 4.47 4.00

Competitive Comparison of Shanghai Henlius Biotech's PB Ratio

For the Biotechnology subindustry, Shanghai Henlius Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's PB Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's PB Ratio falls into.


;
;

Shanghai Henlius Biotech PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Shanghai Henlius Biotech's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=37.70/5.92
=6.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Shanghai Henlius Biotech  (HKSE:02696) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Shanghai Henlius Biotech PB Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Qatar Investment Authority 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines